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Consistent Fluctuations in Quantities of Circulating
Immune Complexes During Progressive and
Regressive Phases of Tumor Growth
J. Charles Jennette, MD
Circulating immune complexes (CIC) were quantitated by a Raji cell radioimmunoassay
in sera from Brown Norway rats bearing progressing or regressing methylcholanthrene-
induced sarcomas. Quantitative profiles of CIC over time were related to tumor dose, tu-
mor mass, and the regressive or progressive course of tumor growth. Animals bearing
progressing tumors demonstrated an initial peak of CIC levels by 7 weeks but thereafter
displayed a persistent decline in quantities of CIC despite continued tumor growth. Ani-
mals bearing regressing tumors were found to have a more directly proportional relation-
ship between the tumor mass and the levels of CIC, but the appearance and dis-
appearance of CIC lagged slightly behind the appearance and disappearance of the
tumor. These data are almost identical to data previously published detailing quantities
of CIC in BN and Lewis rats bearing Moloney sarcomas and are similar to fluctuations in
CIC observed in animals and humans hosting a number of disparate neoplasms. (Am J
Pathol 1980, 100:403-410)
CIRCULATING IMMUNE COMPLEXES (CIC) have been detected
in experimental animals and man bearing a variety of malignant neo-
plasms.'-15 A number of investigators have demonstrated tumor-associated
neoantigens and the resultant antibodies within these CIC.1-4'8'1' The
functional role of tumor-associated CIC in the regulation of tumor growth
or of immunologic host response has not been clearly defined. Support for
and elucidation of such a role will require a knowledge of the quantities of
immune complexes present in the circulation during various phases of tu-
mor growth (eg, progression, regression). If consistent associations can be
defined between quantitative or qualitative characteristics of tumor-asso-
ciated CIC and the growth potential of the inciting neoplasm, determina-
tion of such characteristics could be useful in the assessment of the prog-
nosis or monitoring the therapeutic response in patients bearing
malignancies. The author and Dr. J. D. Feldman have previously demon-
strated predictably variable quantities of CIC during various phases of
Moloney sarcoma growth.7 The present study substantiates this phenome-
non in a methylcholanthrene-induced tumor system that should generate
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tumor-associated CIC devoid of virus-related antigens and antibodies.
Such an experimental system is more analogous to most human malignant
neoplasms.
Materials and Methods
Tumor cells derived from a methylcholanthrene-induced Brown Norway rat sarcoma
(MCS) were cultured as monolayers in minimal essential medium (MEM) containing 10%O
fetal calf serum (FCS) and antimicrobial agents. MCS for injection had been passaged
through 46 transfer generations.
Three-month-old male Brown Norway (BN) rats were injected subcutaneously in the
left thigh with 0.4 ml of MEM containing either 2 x 10O MCS, 5 x 105 MCS, or no MCS.
Animals bearing neoplasms that displayed progressive growth during observation will be
designated progressors, and those bearing transient neoplasms that regressed will be desig-
nated regressors. Rats were evaluated for 111 days or until death at intervals ranging from
3 days to 20 days, tumor size was assessed, and serum samples were obtained and stored at
-70 C until they were assayed for immune complexes.
A Raji cell radioimmunoassay was used to quantitate immune complexes in sera. The
modification of the Raji cell assay employed in this study has been described previously.7
In brief, serum samples were incubated with Raji cells, and then unbound serum constitu-
ents were washed away. '"I-labeled rabbit antibody to rat IgG was added to the Raji cells
and incubated. Unbound antibody was washed away, and radioactivity bound to the Raji
cells was counted. We determined specifically bound radioactivity by subtracting radio-
activity bound to Raji cells incubated with serum obtained from the same rat before injec-
tion with MCS and/or MEM from the radioactivity bound after assay of a sample. All de-
terminations for a given serum sample were performed in triplicate. The quantity of CIC
in a serum sample was expressed as micrograms of aggregated rat IgG equivalents per mil-
liliter of test serum (,Lg RAggG eq/ml). This value was calculated from a standard curve
determined for binding of known amounts of heat-aggregated rat IgG (RAggG) to Raji
cells.7 The sensitivity of this Raji cell radioimmunoassay for detecting RAggG was 8 ,tg
RAggG/ml serum or less.
Results
Control BN Rats
In 4 BN rats receiving subcutaneous injections of MEM alone no pal-
pable masses developed. Sera taken from these animals on a schedule
identical to that for sampling of MCS-bearing rats had a mean CIC value
of 3.2 ,g RAggG eq/ml with an SD of 8.0. For the tumor-bearing rats any
CIC values greater than 19.2 ,tg RAggG eq/ml (mean of control sera plus
2 SD) were considered significant. Ninety-five percent of the control val-
ues were less than 19.2 jig RAggG eq/ml. These control data are similar to
data obtained for 15 control BN rats in a previous study,7 where there was
a mean value of 5.6 ,Ig RAggG eq/ml with an SD of 8.6.
Progressor BN Rats Inoculated With 2 x 107 MCS
In all 8 BN rats given injections subcutaneously of 2 x 107 MCS prog-
ressing tumors developed leading to death at from 41 to 91 days after in-
oculation. The size of the tumor was maximal at death and averaged 62.6
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mm in mean diameter (SD = 14.8). Significant levels of circulating im-
mune complexes were present in 7 animals by Day 15 and in all 8 by Day
18. Levels of CIC reached a maximum after an average of 38.4 days
(range = 34-48 days), then declined, despite continued tumor growth, but
remained significantly above control values in 7 of the 8 animals. The av-
erage maximum level of CIC attained was 215 ,ig RAggG eq/ml (range =
128-368). Text-figure 1 depicts the mean CIC level and mean tumor di-
ameter at various time points during tumor growth in the 8 BN rats that
received 2 x 107 MCS.
Progressor BN Rats Inoculated With 5 x 105 MCS
In 2 of 8 BN rats given injections subcutaneously of 5 x I10 MCS prog-
ressing tumors developed, but the animals were still alive at the end of the
observation period (131 days), with an average tumor diameter of 46 mm.
The quantitative profile of CIC in these animals was similar to that in the
BN rats receiving 2 x 107 MCS, except for a slight temporal shift to the
right, with CIC reaching significant levels at Days 21 and 27. CIC maxi-
mums were attained on Days 41 and 48 and measured 260 and 164 Mig
RAggG eq/ml. After peaking, CIC levels declined but remained signifi-
cantly above control levels during observation. Text-figure 2 represents
the average CIC levels and tumor diameters over time for these prog-
ressor animals receiving 5 X 10 MCS.
Regressor BN Rats Inoculated With 5 x 105 MCS
In 6 of 8 BN rats given subcutaneous injections of 5 X 105 MCS regress-
ing tumors developed that reached maximum diameters averaging 27.5
TEXT-FIGURE I-The dashed line and
open circles represent the mean tu-
mor diameter of 8 progressor BN rats
that received 2 x 107 MCS (SD at
each point ranges from 0.7 to 2.1
mm). The solid line and closed circles
represent the mean of triplicate de-
terminations of CIC expressed as ,ug
RAggG eq/ml and plotted against
day after tumor inoculation. Non-
specific binding obtained with pre-
injection sera has been subtracted.
Vertical bars indicate the SEM. The
shaded area represents the control
mean + 2 SD.
I
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TEXT-FIGURE 2-The dashed line and
open circles represent the average
tumor diameter of 2 progressor BN
rats that received 5 x 105 MCS (the
mean of the difference between mea-
surements at all points is 4.1 mm).
The solid line and closed circles rep-
resent the mean of triplicate determi-
nations of CIC expressed as ,ug
RAggG eq/ml and plotted against
day after tumor inoctulation. Non-
specific binding obtained with pre-
injection sera has been subtracted.
Vertical bars indicate the SEM. The
shaded area represents the control
mean + 2 SD.
mm (SD, 2.3) after a mean interval of 38.7 days (range, 26-34 days). Tu-
mors could no longer be palpated by Day 57. The average interval before
elevation of CIC to significant levels was 24.0 days (range, 21-27 days).
Levels of CIC attained maximums after an average of 30.5 days (range,
26-34 days) and thereafter declined, reaching insignificant levels by an av-
erage of 64.2 days (range, 48-70 days). Text-figure 3 shows the mean CIC
levels and mean tumor diameters over time for the 6 regressor animals re-
ceiving 5 X 105 MCS. The ascending limb of this quantitative CIC profile
is similar to that for the progressors receiving 5 X 105 MCS, but the de-
scending limb is substantially more precipitous and reaches undetectable
levels.
TEXI -FIGURF 3-The dashed line
and open circles represent the
mean ttumor diameter of 6 regressor
BN rats that received 5 X 10' MCS
(SD at each point ranges from 0.8
to 2.2 mm). The solid line and
closed circles represent the mean of
triplicate determinations of CIC
expressed as jig RAggG eq/mi and
plotted against day after tuimor in-
oculation. Nonspecific binding ob-
tained with preinjection sera has
been subtracted. Vertical bars in-
dicate the SEM. The shaded area
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Discussion
These data demonstrate predictable fluctuations in quantities of CIC
during different phases of methylcholanthrene-induced sarcoma growth in
BN rats. The levels of CIC attained and the time-course of detection were
related to tumor dose, tumor mass, and the regressive or progressive
course of tumor growth. Progressor animals that received 2 X 107 MCS
and progressor animals that received 5 x 105 MCS had similarly con-
toured quantitative profiles; however, the profile of the latter group had a
temporal shift to the right. Both groups demonstrated that levels of CIC
are not always directly proportional to tumor mass, as evidenced by the
terminal decline in complexes despite continued tumor enlargement. In
addition, the CIC profiles appeared more dependent upon the nature of
the tumor growth (ie, progression) than the mass of the tumor, in that the
progressors receiving 5 X 105 MCS and having smaller neoplasms had
quantities of CIC similar to those in animals receiving 2 x 107 MCS and
having larger neoplasms. Animals with regressing tumors induced by the
inoculation of 5 x 105 MCS displayed a more directly proportional rela-
tionship between tumor mass and levels of CIC, but the appearance and
disappearance of CIC lagged slightly behind the appearance and dis-
appearance of the tumor.
These data from a chemically induced sarcoma system in BN rats are
remarkably similar to previous data detailing levels of CIC in BN Mo-
loney sarcoma-bearing BN and Lewis rats.7 In progressor BN rats that de-
veloped high levels of CIC during the first month of Moloney sarcoma
growth, there was a terminal decline in CIC despite continued tumor
growth. In both BN and Lewis rats bearing regressing BN Moloney sar-
comas, there were transient elevations in CIC, with maximums closely fol-
lowing peaks in tumor growth.
Hoffken and associates,'4 using a Clq-binding assay on sera from rats
bearing progressing chemically induced tumors have also demonstrated
peaking of levels of CIC followed by decline to insignificant levels despite
continued tumor growth. They have also observed the return of CIC mea-
surements to normal after tumor excision, a situation similar to that of the
regressor animals with transient elevation of CIC reported here.
Suggestive, but less conclusive evidence for similar associations in man
between levels of CIC and neoplastic growth phases have been observed.
Rossen and associates,'° employing a Clq-binding assay, found greater
quantities of CIC in patients who had neoplastic disease of shorter dura-
tion than in those who had borne neoplasms for longer periods. Steele and
co-workers 15 describe one patient with colorectal cancer, followed until
death, who showed a terminal fall in CIC. And in patients receiving ap-
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parently successful surgical therapy for breast cancer, Hoffken 13 demon-
strated with a Clq radioimmunoprecipitation assay loss of elevated CIC.
Therefore, in animals and men and women bearing a number of dis-
parate neoplasms there is a consistent relationship between the quantities
of CIC demonstrable in the serum and the status of the neoplastic process.
With progressing tumors, quantities of CIC are not always directly pro-
portional to neoplastic growth, suggesting that declining levels of CIC
might not always correlate with a good prognosis. To date, inadequate
data have been published to conclusively delineate the relationship be-
tween neoplastic growth potential and levels of associated CIC; however,
there is mounting evidence that predictable fluctuations in quantities of
CIC do occur during various phases of tumor growth.
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